Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy

被引：2

作者：

Perez, Jorge M. Ramos ^{[1
]}

Tinajero, Jose ^{[2
]}

Ngo, Dat ^{[2
]}

Zhang, Jianying ^{[3
,4
]}

Koller, Paul B. ^{[1
]}

Agrawal, Vaibhav ^{[1
]}

Pourhassan, Hoda ^{[1
]}

Al Malki, Monzr M. ^{[5
]}

Salhotra, Amandeep ^{[1
]}

Ali, Haris ^{[1
]}

Aribi, Ahmed ^{[1
]}

Sandhu, Karamjeet S. ^{[1
]}

Arslan, Shukaib ^{[1
]}

Otoukesh, Salman ^{[1
]}

Amanam, Idoroenyi ^{[1
]}

Artz, Andrew S. ^{[1
]}

Becker, Pamela S. ^{[1
]}

Stewart, Forrest M. ^{[1
]}

Smith, Eileen P. ^{[1
]}

Curtin, Peter ^{[1
]}

Forman, Stephen J. ^{[1
]}

Nakamura, Ryotaro ^{[1
]}

Pullarkat, Vinod A. ^{[1
]}

Marcucci, Guido ^{[1
]}

Stein, Anthony S. ^{[1
]}

Aldoss, Ibrahim ^{[1
]}

Ball, Brian J. ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA 91010 USA

[2] City Hope Natl Med Ctr, Dept Pharm, Duarte, CA USA

[3] City Hope Natl Med Ctr, Dept Computat & Quantitat Med BRI, Duarte, CA 91010 USA

[4] City Hope Natl Med Ctr, Dept Computat & Quantitat Med, Beckman Res Inst, Duarte, CA USA

[5] City Hope Med Ctr, Duarte, CA USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-170867

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

615

引用

页码：9039 / 9040

页数：2

共 50 条

[11] Evaluation of 3-day azithromycin or 5-day cefaclor in comparison with 10-day amoxicillin for treatment of tonsillitis in children
Li, Peng
Jiang, Genqin
Shen, Xiaofei
[J]. CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2019, 97 (10) : 939 - 944
[12] A Phase 1 Study Evaluating ASTX727 (decitabine and cedazuridine) and Venetoclax Combination Therapy in Newly Diagnosed AML Patients Unfit for Intensive Induction Chemotherapy
Nannis, Gabriel N.
Griffiths, Elizabeth A.
Savona, Michael R.
Odenike, Olatoyosi
Roboz, Gail J.
O'Connell, Casey L.
Dillingham, Jacqueline
Wason, Prieya
Zhu, Lixia
Chan, Danna
Keer, Harold N.
Oganesian, Aram
Dao, Kim-Hien
DiNardo, Courtney D.
[J]. BLOOD, 2021, 138
[13] Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy
Kambhampati, Suman
McMahon, Christine M.
Eghtedar, Alireza
Pollyea, Daniel A.
de Botton, Stephane
Pigneux, Arnaud
Cherry, Mohamad
Ball, Brian J.
Borthakur, Gautam
Cluzeau, Thomas
Schiller, Gary J.
Hu, Beibei
Volkert, Angela
Gausman, Joanie Aasen
Hodgson, Graeme
Roth, David A.
Warlick, Erica D.
Kelly, Michael J.
Stein, Eytan
[J]. BLOOD, 2022, 140 : 3333 - 3335
[14] Efficacy of 5-and 10 Day Decitabine Schedules Not Different in Elderly Patients With AML
不详
[J]. ONCOLOGY-NEW YORK, 2020, 34 (10): : 430 - 430
[15] Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Jacobien R. Hilberink
Isabelle A. van Zeventer
Dana A. Chitu
Thomas Pabst
Saskia K. Klein
Georg Stussi
Laimonas Griskevicius
Peter J. M. Valk
Jacqueline Cloos
Arjan A. van de Loosdrecht
Dimitri Breems
Danielle van Lammeren-Venema
Rinske Boersma
Mojca Jongen-Lavrencic
Martin Fehr
Mels Hoogendoorn
Markus G. Manz
Maaike Söhne
Rien van Marwijk Kooy
Dries Deeren
Marjolein W. M. van der Poel
Marie Cecile Legdeur
Lidwine Tick
Yves Chalandon
Emanuele Ammatuna
Sabine Blum
Bob Löwenberg
Gert J. Ossenkoppele
Gerwin Huls
[J]. Blood Cancer Journal, 13
[16] Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
Hilberink, Jacobien
van Zeventer, Isabelle
Chitu, Dana
Pabst, Thomas
Klein, Saskia
Stussi, Georg
Griskevicius, Laimonas
Valk, Peter J. M.
Cloos, Jacqueline
van de Loosdrecht, Arjan
Breems, Dimitri
van Lammeren-Venema, Danielle
Boersma, Rinske
Jongen-Lavrencic, Mojca
Fehr, Martin
Hoogendoorn, Mels
Manz, Markus
Sohne, Maaike
Kooy, Rien van Marwijk
Deeren, Dries
van der Poel, Marjolein W. M.
Legdeur, Marie Cecile
Tick, Lidwine
Chalandon, Yves
Ammatuna, Emanuele
Blum, Sabine
Lowenberg, Bob
Ossenkoppele, Gert
Huls, Gerwin
[J]. BLOOD CANCER JOURNAL, 2023, 13 (01)
[17] Efficacy or 10-Day and 5-Day Concomitant Therapy for Helicobacter pylori Eradication in Thai Patients With Non Ulcer Dyspepsia
Kongchayanun, Chutima
Mahachai, Varocha
Pornthisarn, Bubpha
Amornsawadwanana, Surachai
Vilaichone, Ratha-korn
[J]. GASTROENTEROLOGY, 2011, 140 (05) : S879 - S879
[18] Disease response and survival outcomes in acute myeloid leukemia (AML) patients unfit for chemotherapy treated with 10-day decitabine as initial therapy.
Gourdin, Theodore Stewart
Bhatnagar, Bhavana
Duffy, Alison P.
Tidwell, Michael
Ning, Yi
Sausville, Edward A.
Baer, Maria R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[19] Remission induction in newly diagnosed AML patients aged 55-75 years using a 5 day idarubicin schedule in combination with cytarabine
Douer, D
Saven, A
Watkins, K
Gollard, R
Kahn, A
Piro, L
Levine, AM
[J]. BLOOD, 1995, 86 (10) : 3015 - 3015
[20] Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine
Blum, William
Garzon, Ramiro
Klisovic, Rebecca B.
Schwind, Sebastian
Walker, Alison
Geyer, Susan
Liu, Shujun
Havelange, Violaine
Becker, Heiko
Schaaf, Larry
Mickle, Jon
Devine, Hollie
Kefauver, Cheryl
Devine, Steven M.
Chan, Kenneth K.
Heerema, Nyla A.
Bloomfield, Clara D.
Grever, Michael R.
Byrd, John C.
Villalona-Calero, Miguel
Croce, Carlo M.
Marcucci, Guido
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (16) : 7473 - 7478

← 1 2 3 4 5 →